Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (PASSAGE)

About This Trial

Phase IV: a long term prospective multinational parallel-cohort study monitoring safety in patients with MS newly started on Fingolimod once daily or treated with another approved disease modifing therapy.

  • Status: Enrolling now
  • Location: Miami Valley Hospital South
  • Principal Investigator: Tracy Eicher, MD

For more information about this study, visit ClinicalTrials.gov:  NCT01442194

Contact Us

If you would like information about participating in this study, contact:

Don McHone, RN, BSN
937-208-4451
djmchone@premierhealth.com